# Stem Cells Note

Quickly create a rich document.

# California new law: Senate Bill 512

---

- SB 512要求任何正在执行非FDA批准的干细胞治疗的医疗保健提供者在其办公室发布通知，并向每位患者提供说明该程序未经FDA批准的说明。

SB 512 requires any health care provider who is administering `non-FDA` approved stem cell treatments to post a `notice` in their office and provide a handout to each patient stating that the procedure has not been approved by the FDA.

[Bill Text - SB-512 Health care practitioners: stem cell therapy.](http://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=201720180SB512)

`notice` 要求：

1. In a prominent display in an area visible to patients in the health care practitioner’s office and posted conspicuously in the entrance of the health care practitioner’s office. These notices shall be at least eight and one-half inches by 11 inches and written in no less than 40-point type.  在医疗保健从业者办公室中的患者可见的区域中突出显示，并在保健医生办公室的入口处明显张贴。这些通知应至少为8.5英寸×11英寸，并且写入文字不少于40磅的类型。
2. Prior to providing the initial stem cell therapy, a health care practitioner shall provide the patient with the notice described in paragraph (1) in writing. The notice shall be at least eight and one-half inches by 11 inches and written in no less than 40-point type. 在提供初始干细胞治疗之前，医疗保健医生应以书面形式向患者提供第（1）款所述的通知。通知应至少为8.5英寸×11英寸，并写入文字不少于40磅的类型。
3. This section does not apply to a health care practitioner licensed under this division who has obtained approval for an investigational new drug or device from the FDA for the use of HCT/Ps. 本节不适用于获得该部门许可的医疗从业者，该医疗从业者已获得FDA批准使用HCT / Ps的研究性新药或设备。

---

# Texas law: HB 810

---

- 德克萨斯州州长Greg Abbott昨天 `2017.7.14` 签署了一项法案，允许该州的诊所和公司在未经联邦法律要求的测试和批准的情况下向人们提供未经证实的干细胞干预措施。就像在30多个州涌现出来的“试行权”法案一样，这项措施旨在让绝症患者获得实验性治疗，而无需美国食品和药物管理局（FDA）的监督。

Texas Governor Greg Abbott yesterday signed a bill allowing clinics and companies in the state to offer people unproven stem cell interventions without the testing and approval required under federal law. Like the “right to try” laws that have sprung up in more than 30 states, the measure is meant to give desperately ill patients access to experimental treatments without oversight from the U.S. Food and Drug Administration (FDA).

[Texas has sanctioned unapproved stem cell therapies. Will it change anything?](https://www.sciencemag.org/news/2017/06/texas-has-sanctioned-unapproved-stem-cell-therapies-will-it-change-anything)

- HB810将允许患有严重慢性或绝症的人在诊所治疗。 这些诊所必须从成人组织中分离治疗性干细胞 - 例如患者自身的脂肪 - 用于治疗，前提是医生在考虑所有其他选择后推荐它，且由在医院或医学院注册的医生执行，并且由机构审查委员会（IRB）监督。法案还要求在临床试验中已经对人类进行了相同的干预测试。该法律制定了比联邦法规更广泛的治疗方法，这些法规已经免除了FDA长期批准程序中的某些干细胞干预措施，条件是这些细胞只是“最低限度地操纵”并且执行它们在体内通常具有的相同功能。

HB810 will allow people with severe chronic or terminal illness to be treated at a clinic that purports to isolate therapeutic stem cells from adult tissue—such as a patient’s own fat—if their doctor recommends it after considering all other options, and if it’s administered by a physician at a hospital or medical school with oversight from an institutional review board (IRB). It also requires that the same intervention already be tested on humans in a clinical trial. The law sanctions a much broader set of therapies than federal rules, which already exempt certain stem cell interventions from FDA’s lengthy approval process, provided the cells are only “minimally manipulated” and perform the same function they normally have in the body.

**Can I get stem cell therapy in Texas now?**

- 还不行。 HB 810于2017年9月生效。但是，它必须先由2个州政府机构来制定法规。第一步是让德克萨斯医疗委员会完成他们的规则制定过程。现在，德克萨斯州卫生和公共服务部门正在确定哪些条件可以得到治疗。这个决定预计在2018年秋天。在那之前，没有诊所在HB 810下运作。

No, not yet. HB 810 went into effect in Sept. 2017. However, it had to go before 2 state agencies to define regulations. The first step was for the Texas Medical Board to do their rule making process. It is now before the Texas State Department of Health and Human Services to establish which conditions can be treated. This decision is expected in the fall of 2018. We will publish when this is available. Until that time, there are no clinics operating under HB 810.

[Patients for Stem Cells](https://patientsforstemcells.org/)

# FDA 的态度

---

FDA有权在美国监管干细胞产品。今天，医生通常在移植手术中使用来自骨髓或血液的干细胞来治疗患有癌症和血液和免疫系统疾病的患者。除了有限的例外，研究产品还必须经过彻底的FDA审查过程，因为研究人员准备确定产品在控制良好的人体研究中的安全性和有效性，称为临床试验。 FDA已经审查了许多用于这些研究的干细胞产品。作为FDA审查的一部分，研究人员必须说明每种产品的生产方式，以便FDA能够确保采取适当的措施来确保产品的安全性，纯度和强度（效力）。 FDA还要求动物研究提供足够的数据，以帮助评估与产品使用相关的任何潜在风险。 （您可以在FDA网站上了解有关临床试验的更多信息。）也就是说，一些诊所可能会在不提交IND的情况下不恰当地宣传干细胞临床试验。一些诊所也可能错误地宣传FDA审查和批准干细胞治疗是不必要的。 `但是，当临床试验不是在IND下进行时，这意味着FDA没有审查实验性治疗以确保其合理安全。所以要小心这些治疗方法`(But when clinical trials are not conducted under an IND, it means that the FDA has not reviewed the experimental therapy to help make sure it is reasonably safe. So be cautious about these treatments.)

关于FDA批准的干细胞衍生产品

FDA批准在美国使用的唯一基于干细胞的产品包括源自脐带血的血液形成干细胞（造血祖细胞）。这些产品被批准用于影响涉及血液生成的身体系统的病症的患者（称为“造血”系统）。这些FDA批准的干细胞产品列于FDA网站上。骨髓也用于这些治疗，但通常不受FDA对此用途的监管。(These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood (called the “hematopoietic” system). These FDA-approved stem cell products are listed on the FDA website. Bone marrow also is used for these treatments but is generally not regulated by the FDA for this use.)

[FDA Warns About Stem Cell Therapies](https://www.fda.gov/forconsumers/consumerupdates/ucm286155.htm)